Please login to the form below

Not currently logged in
Email:
Password:

haemophilia A

This page shows the latest haemophilia A news and features for those working in and with pharma, biotech and healthcare.

NHS England says yes to Roche's Hemlibra

NHS England says yes to Roche's Hemlibra

Roche’s new haemophilia A treatment Hemlibra has gained a valuable market access approval from NHS England. ... There are an estimated 5, 930 patients registered with Haemophilia A in the UK, of which 230 have factor VIII inhibitors.

Latest news

More from news
Approximately 15 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • ‘How is your day?’ ‘How is your day?’

    World champion cyclist Alex Dowsett lives with severe haemophilia. He also speaks for ‘How Is Your Day? ’. ... plasma. Haemophilia is a condition that can be treated by both laboratory-produced recombinant plasma therapies or medicines made from

  • Deal Watch January 2018

    Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... Strategically caplacizumab represented a good

  • The good, the bad and the ugly The good, the bad and the ugly

    However, investors fear that challenges in the $11bn haemophilia market could lead to a slump in the haemophilia business it inherited through the Baxalta purchase. ... These two players will have a comfortable advantage over their nearest rival - Roche (

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

  • Deal Watch August 2016 Deal Watch August 2016

    Sanofi sought to take control of Medivation's board using a paper vote. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV vector and the academic

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Freeline comprises some of the world’s leading experts in gene therapy, haemophilia and other debilitating disorders and I look forward to working closely with them to demonstrate the potential of ... She has also worked at Novo Nordisk as senir vice

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Living with haemophilia – the power of knowledge

    Haemophilia is a genetic disorder that prevents blood from clotting [1]. It is a predominantly male disorder, with haemophilia A occurring in 1 in 5, 000 live male births [1]. ... Untreated, haemophilia can be extremely debilitating, making everyday

  • Attracting doctors to low-demand specialties: A role for industry?

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics